Mineralys Therapeutics, Inc. (MLYS)

In September 2025, the company closed an upsized $287.5 million underwritten public offering of common stock. In November 2025, data for lorundrostat in chronic kidney disease and hypertension was presented at the American Society of Nephrology (ASN) Kidney Week 2025, which coincided with strong gains in the stock. Also in November 2025, Mineralys Therapeutics reported its third-quarter 2025 financial results, highlighting a strong cash position and an NDA plan, which led to a positive reaction in the stock. In December 2025, the company's Phase 3 Launch-HTN trial of lorundrostat was recognized in the inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup, also aligning with strong stock gains. In late 2025, Mineralys Therapeutics filed a New Drug Application (NDA) for lorundrostat after completing three positive clinical trials in 2025. In January 2026, Mineralys Therapeutics provided a corporate update and announced participation in an upcoming LifeSci Partners Corporate Access Event. Also in January 2026, CEO Jon Congleton sold shares of the company. Positive clinical and financial milestones for lorundrostat have historically coincided with favorable price reactions, while non-clinical corporate events have shown more muted or mixed impacts. The stock experienced a significant increase between January 2025, and January 2026.

The demand for Mineralys Therapeutics' product, lorundrostat, is unlikely to exhibit significant seasonality, as demand for pharmaceuticals treating chronic conditions is generally stable throughout the year. The company's current focus is on clinical development and regulatory approval, rather than commercial sales, further minimizing any immediate impact of demand seasonality.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases driven by abnormally elevated aldosterone. The company's primary product candidate is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor (ASI). Mineralys Therapeutics is initially developing lorundrostat for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The company was founded in May 2019 and was formerly known as Catalys SC1, Inc.

Mineralys Therapeutics, Inc. is headquartered in Radnor, Pennsylvania, United States and develops medicines to target diseases in the United States.

Mineralys Therapeutics generally holds a positive brand reputation, particularly within the investment community. The company has received a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.63. Analysts have set an average 12-month stock price target of $47.33, indicating a potential upside from a recent price. The company's MarketRank™ score indicates it performs better than 62% of companies evaluated by MarketBeat. Positive topline results from its pivotal Phase 3 trials for lorundrostat, recognition of the Phase 3 Launch-HTN trial in the Journal of the American Medical Association (JAMA) “Research of the Year” Roundup, successful completion of three positive clinical trials for lorundrostat in 2025 and the subsequent filing of an NDA, and positive data presentations at major medical conferences have positively affected its reputation. Some cautious sentiment exists due to its clinical-stage nature, lack of revenue, negative earnings, and significant cash flow deficits. Insider selling can also be a point of investor consideration.

Mineralys Therapeutics, Inc. has a significant institutional ownership, with a majority of its stock held by institutional shareholders including Catalys Pacific, LLC, RA Capital Management, L.P., Samsara BioCapital, LLC, BlackRock, Inc., and Vanguard Group Inc. Insiders also hold a significant portion of the company's stock. Srinivas Akkaraju is the largest individual shareholder.